Table 3.

Incidence rates and HRs for ESRD associated with treatment-resistant HTN among REGARDS study participants, stratified by level of ACR and eGFR

	No treatment-resistant HTN		Treatment-resistant HTN		Adjusted† HR (95% CI)
	No. events/No. at risk	IR (95%CI)	No. events/ No. at risk	IR (95% CI)
ACR
< 30 mg/g	14/7,222	0.32 (0.19–0.53)	9/1,289	1.14 (0.59–2.19)	1.55 (0.61–3.94)
≥ 30 mg/g	28/605	8.20 (5.66–11.88)	101/858	22.28 (18.33–27.08)	2.54 (1.61–4.00)
eGFR
≥ 60 mL/min/1.73 m2	12/6,987	0.28 (0.16–0.49)	16/1,549	1.70 (1.04–2.78)	3.57 (1.58–8.07)
45–59 mL/min/1.73 m2	3/564	0.91 (0.29–2.82)	15/337	8.13 (4.90–13.48)	6.53 (1.86–22.96)
<45 mL/min/1.73m2	27/276	18.96 (13.00–27.64)	79/261	66.66 (53.47–83.10)	3.22 (2.01–5.15)

Abbreviations and definitions: CI, confidence interval; ESRD: end-stage renal disease; REGARDS, Reasons for Geographic and Racial Differences in Stroke; HTN, hypertension; HR, hazard ratio; IR, incidence rate per 1,000 person-year; ACR: albumin-creatinine ratio; eGFR: estimated glomerular filtration rate

^†Propensity-adjusted for predicted probability of treatment-resistant HTN based on age, race, sex, region of residence, education, income, physical activity, current smoking, alcohol use, statin use, waist circumference, diabetes, total cholesterol, high-density lipoprotein cholesterol, C-reactive protein, history of myocardial infarction, and history of stroke.